Wells Fargo Downgrades Nike to Equal Weight on GLP-1 Mega-Trend

Wells Fargo has downgraded Nike (NYSE:NKE) to Equal Weight from Overweight, while cutting its price target to $45 from $55. The call comes as Nike stock is already under pressure, down roughly 30% year-to-date and 25% over the past year.

Rating Change

• Previous Rating: Overweight
• New Rating: Equal Weight
• Previous Price Target: $55
• New Price Target: $45

Analyst's Rationale

Wells Fargo analysts believe the GLP-1 mega-trend, referring to weight-loss drugs, poses a significant threat to the athletic wear industry and Nike in particular. As more people use these drugs, physical activity levels and consequently demand for athletic apparel may decline. This contrarian view challenges the prevailing optimism around Nike.

Context

Nike shares have already lost about 30% of their value year-to-date. While some analysts remain bullish, Wells Fargo's downgrade adds a new layer of caution. The stock is trading near its 52-week lows.

What It Means for Investors

The downgrade reflects a cautious near-term outlook for Nike, driven by structural concerns about changing consumer behavior due to GLP-1 drugs. Investors should monitor sales trends in coming quarters to assess the actual impact of this mega-trend.